Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strategic M&A: Sanofi Buys Principia Biopharma For $3.7bn

Removes Sanofi Royalty Payments on Brain-Penetrant SAR442168

Executive Summary

Sanofi is paying for $3.68bn cash for Principia to get the US biotech’s drug development platform and nascent pipeline, including a brain-penetrant BTK inhibitor in Phase III for multiple sclerosis.

You may also be interested in...



Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study

Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.

Biogen Partners With InnoCare To Keep Up With BTK Inhibitor Leaders in MS

BTK Inhibitors could be a major advance multiple sclerosis therapy, and Biogen has bought into a potential challenger to Phase III frontrunner from Sanofi and Roche.

Sanofi Upbeat On Itepekimab, Rilzabrutinib And Oral IRAK4 Protein Degrader

Sanofi outlines progress on developing a differentiated R&D pipeline in immunology, including novel ways of addressing COPD, atopic dermatitis and autoimmune disorders.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC142799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel